KN060

DRUG2 trials

Sponsors

Suzhou Alphamab Co., Ltd.

Conditions

End-Stage Renal Disease Requiring HaemodialysisHypertension

Phase 1

To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension

RecruitingNCT07191899

Suzhou Alphamab Co., Ltd.Hypertension

Start: 2025-08-05End: 2027-12-30Target: 60Updated: 2025-09-25

To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients

RecruitingNCT07201467

Suzhou Alphamab Co., Ltd.End-Stage Renal Disease Requiring Haemodialysis

Start: 2025-08-22End: 2027-12-15Target: 12Updated: 2025-10-01